Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date

Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date

Pankit Vachhani, Hongbin Chen Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA Abstract: Immunotherapy with immune checkpoint inhibitors has opened a new arena in cancer therapeutics. Pembrolizumab is a highly selective anti-programmed cell death protein 1 (PD-1) antibody th...

Full description

Bibliographic Details
Main Authors: Vachhani P, Chen H
Format: Article
Language:English
Published: Dove Medical Press 2016-09-01
Series:OncoTargets and Therapy
Subjects:
pembrolizumab
KEYNOTE
non-small cell lung cancer
Online Access:https://www.dovepress.com/spotlight-on-pembrolizumab-in-non-small-cell-lung-cancer-the-evidence--peer-reviewed-article-OTT

Internet

https://www.dovepress.com/spotlight-on-pembrolizumab-in-non-small-cell-lung-cancer-the-evidence--peer-reviewed-article-OTT

Similar Items